Status:
COMPLETED
AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
Lead Sponsor:
University Hospital, Limoges
Conditions:
Hematopoietic Stem Cell Transplantation
Cytomegalovirus Infections
Eligibility:
All Genders
18+ years
Brief Summary
Cytomegalovirus (CMV) is a ubiquitous herpesvirus that represent a major cause of morbidity in haematopoietic stem cell transplants (HSCT) recipients, mostly through reactivation of the recipient's vi...
Detailed Description
Cytomegalovirus (CMV) is a ubiquitous herpesvirus that represent a major cause of morbidity in haematopoietic stem cell transplants (HSCT) recipients, mostly through reactivation of the recipient's vi...
Eligibility Criteria
Inclusion
- Inclusion Criteria :
- • Candidate (adult) for an allograft of hematopoietic stem cells for which a decision of transplant is made and willing to participate in the cohort.
- Exclusion Criteria :
- CMV-seronegative patient receiving a negative CMV donor graft ;
- Patient having signed the consent but not grafted ;
- Patient included in a clinical study on an anti-CMV molecule ;
- Non-insured social patient ;
Exclusion
Key Trial Info
Start Date :
September 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2025
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04690933
Start Date
September 24 2020
End Date
November 30 2025
Last Update
December 15 2025
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de LIMOGES
Limoges, Limoges, France, 87045
2
CHU
Amiens, France
3
CHU
Angers, France
4
CHU
Besançon, France